Table 1. Characteristics of study participants.
| Characteristics | Study subjects | ||||
|---|---|---|---|---|---|
| n (%) | Total (N=48) | Type 1 (N=7) | Type 2 (N=41) | P value | |
| Sex | male | 36 (75) | 3 (43) | 33 (81) | 0.043 |
| Age (y) | mean (S.D.) | 57.9 (12.5) | 47.3 (14.6) | 59.8 (11.4) | 0.029 |
| median (range) | 61.0 (26–75) | 45.0 (26–66) | 62.0 (28–75) | ||
| Duration of disease(y) | mean (S.D.) | 7.0 (15.0) | 8.0 (8.2) | 12.9 (10.0) | 0.235 |
| median (range) | 9.5 (1–37) | 5.0 (3–26) | 10.0 (1–37) | ||
| HbA1c | mean (S.D.) | 7.44 (1.45) | 7.81 (1.06) | 7.37 (1.51) | 0.160 |
| median (range) | 7.30 (4.9–14.4) | 8.20 (5.9–9.0) | 7.30 (4.9–14.4) | ||
| Body mass index (kg/m2) | mean (S.D.) | 23.8 (3.3) | 23.0 (2.1) | 23.9 (3.5) | 0.365 |
| median (range) | 23.5 (17.0–32.2) | 22.2 (20.8–27.3) | 23.5 (17.0–32.2) | ||
| Treatment of DM | no medication | 5 (10) | 0 (0) | 5 (12) | |
| internal use only | 16 (33) | 0 (0) | 16 (39) | ||
| insulin + | 27 (56) | 7 (100) | 20 (49) | ||
| Treatment of hypertension | received | 21 (44) | 1 (14) | 20 (49) | 0.096 |
| Treatment of hyperlipidemia | received | 17 (35) | 2 (29) | 15 (37) | 0.698 |
| Steroid therapy | received | 0 | 0 | 0 | |
| Dialysis | received | 0 | 0 | 0 | |